Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
No Direct Causal Link between Lecanemab and Death in Clinical Trial: Eisai
A causal link between the Alzheimer’s therapy lecanemab and the death of a subject reported in its clinical trial is unlikely, Eisai said on November 29 in a statement responding to a report by ScienceInsider on the drug’s safety concerns.…
To read the full story
Related Article
BUSINESS
- Asahi Kasei Starts Japan PI of Autoimmune Peptide Candidate
April 21, 2026
- Novartis Japan Chief Urges Pro-Innovation Policies to Sustain Investments
April 21, 2026
- Santen Snags China Rights to 5 Glaucoma Drugs from AbbVie
April 20, 2026
- AbbVie Launches Aquipta Migraine Drug in Japan
April 20, 2026
- Fronteo, Astellas Partner on AI-Driven Drug Target Discovery
April 20, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…